RE:RE:RE:RE:RE:Do we even have confirmation of this p.p??Security better be tight at next AGM!!! ChecKING for eggs, tomatoes, and other flying projectiles better be done at the entrance. People have had enough of this group of leaking, lying, unprofessional, no imagination, insecure bunch of moochers!!!!! The entire lot needs an OSC interview to see who leaked the pp!!! Roger, resign, your stink continues to pervade this company. From Harpos and the other insider telling everyone that you gave them insider info, and now another leak, shut the fuk up! RESIGN!!!!!
macman1519 wrote: Fuking management bullshittt!!! Well done TLT. CERTAIN SELECTED PEOPLE FIND OUT EARLY ABOUT A PP, WHILE REGULAR MUSHROOMS LEFT IN THE DARK!!! FUKKIN UNBELIEVEABLE!! GET THIS MANAGEMENT AND BOARD OUT!!!! UNBELIEVEABLY UNPROFESSIONAL AND ILLEGAL!!! INSIDER INFO REVEALED AND ACTED UPON THE LAST TWO DAYS OF TRADING.
manny, you have lost all credibility, mom and pop continues in our immediate future,!!!
GET A new ceo asap and clear house!!! ESPECIALLY ROG AND WIFE!
NO WONDER WE R SPINNING OUR WHEELS. THIS HAS BEEN GOING FOR A WHILE, AND the ONLY PEOPLE THAT DIDNT KNOW A PP WAS COMING, WERE THE ONES THAT BELIEVED MANNY!! LOL, A DEN OF SCUMMIES HERE! Led by the choir, relax, dont worry, be happy, 25 years, 20 bbennies, what more do u want?
PHARMA ON BOARD, AZZHOLES!!!!!! langosta wrote: Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (the “Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations to safely and effectively destroy various cancers, is pleased to announce that it proposes to conduct a non-brokered private placement offering of up to 5,000,000 units at a price of $0.20 per unit for gross proceeds of up to $1 million. Each unit will consist of one common share of the Company and one common share purchase warrant with each warrant entitling the holder to purchase one common share at an exercise price of $0.30 per share for a period of 24 months.
The Company intends to use the proceeds of the offering for the following:
- Advancement of Phase Ib Non-Muscle Invasive Bladder Cancer clinical study
- Advancement of Phase Ib New Oncology Indication clinical study
- Advancement of TLC-2500 therapeutic laser system
- Working capital and general corporate purposes
Subject to satisfaction of certain customary closing conditions, the offering is expected to close in one or more tranches on or before May 16, 2016.